ARMOR (Analyzing Renal Mechanisms of Creatinine Excretion in Patients On tesaglitazaR)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2004
This is a prospective 24-week, randomized, parallel-group, multi-center, active-controlled (pioglitazone 45 mg) open-label study designed to assess the effects of tesaglitazar 2 mg per day on components of renal excretion of creatinine in type 2 diabetics. The study comprises a 2-week enrollment period, followed by a 24-week double blind treatment period and an 8-week follow-up period
Epistemonikos ID: c32592665d94179adcba5c85e9c00cf675ef433d
First added on: May 04, 2024